MedPath

Clinical Trial News

Glibenclamide Shows Promise in Improving Ambulation After Large Hemispheric Infarction

  • Post-hoc analysis of the Phase 3 CHARM trial indicates that intravenous glibenclamide (CIRARA) significantly improves independent ambulation in patients with large hemispheric infarction (LHI).
  • Patients with lesion volumes under 125 mL treated with CIRARA showed a significantly higher odds ratio for achieving favorable modified Rankin Scale (mRS) scores.
  • CIRARA, when combined with endovascular thrombectomy (EVT), demonstrated a substantial increase in the ability of LHI patients to walk independently at 12 months.
  • Remedy Pharmaceuticals is planning a confirmatory Phase 3 study of CIRARA in LHI, encouraged by the sustained effects and impact on patient ambulation.

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953TerminatedPhase 3
Remedy Pharmaceuticals, Inc.
Posted 8/29/2018

AI-Powered Model Aims to Decode Genetic Variants in Stargardt Disease

  • Researchers are developing an AI model to classify genetic variants of the ABCA4 gene, crucial for understanding Stargardt disease.
  • The model integrates genetic, clinical, and structural data to predict the pathogenicity of previously unclassified variants.
  • This research aims to personalize medicine by identifying appropriate clinical trials and therapies for individuals with Stargardt disease.
  • The NIH-funded project addresses the challenge that nearly 40% of ABCA4 genetic variants are currently unclassified, hindering accurate diagnosis.

RDCA-DAP Boosts Cystic Fibrosis Research with New Data Sets

  • The RDCA-DAP has acquired new datasets from the Cystic Fibrosis Therapeutics Development Network to accelerate cystic fibrosis (CF) research and therapy development.
  • The data sharing initiative seeks to enhance understanding of CF progression, design new clinical outcome measures and biomarkers, and develop disease models.
  • By integrating data into the RDCA-DAP, researchers worldwide can access and leverage data, potentially leading to breakthroughs in CF care.
  • The RDCA-DAP is an initiative run by the Critical Path Institute (C-Path) and funded by the FDA to provide a centralized platform of patient data for rare diseases.

FDA Backs Alpha-Synuclein Assay for Parkinson's Trials, Aiding Drug Development

  • The FDA supports using the α-synuclein seed amplification assay (αSyn-SAA) biomarker in clinical trials for Parkinson's disease and related conditions, potentially accelerating drug development.
  • The decision follows collaboration between The Michael J. Fox Foundation and the Critical Path Institute, leveraging data from the Parkinson's Progression Markers Initiative.
  • αSyn-SAA demonstrates high accuracy in detecting Parkinson's early, even before symptoms, enabling better-targeted therapies and efficient clinical trials.
  • Amprion's SAAmplify-αSYN Biomarker Test is currently the only validated synSAA assay available in the U.S. for improving the diagnosis of Parkinson’s and other synucleinopathies.

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

NCT05853900CompletedPhase 3
Click Therapeutics, Inc.
Posted 3/28/2023

Docetaxel Shows Promise in Reducing Neuropathy for Black Breast Cancer Patients

  • A clinical study reveals that docetaxel is associated with significantly less neuropathy in Black breast cancer patients compared to paclitaxel, potentially improving treatment outcomes.
  • The research addresses disparities in breast cancer treatment, as Black women are more likely to experience severe chemotherapy-induced peripheral neuropathy.
  • The study's design involved collaboration with Black patient advocates to ensure inclusivity and relevance, marking a significant step in addressing healthcare disparities.
  • Findings suggest docetaxel may be the preferred chemotherapy drug for Black women with breast cancer, leading to fewer dose reductions and improved quality of life.

Xolair Receives FDA Approval for Food Allergies After Two Decades

  • Xolair, initially approved for asthma in 2003, has now been FDA-approved for treating food allergies, offering relief to millions with severe allergic reactions.
  • The drug works by intercepting IgE molecules, key triggers of allergic reactions, and has shown significant promise in clinical trials, allowing patients to tolerate previously dangerous foods.
  • A major clinical trial, OUtMATCH, demonstrated that two-thirds of participants on Xolair could consume the equivalent of two and a half peanuts after 16 weeks of treatment.
  • While not a cure, Xolair provides a protective buffer against accidental allergen exposure and can be used in conjunction with oral immunotherapy to enhance safety and effectiveness.

European Commission Approves Encorafenib and Binimetinib Combination for BRAF V600E-Mutant NSCLC

  • The European Commission has approved encorafenib (BRAFTOVI) in combination with binimetinib (MEKTOVI) for treating adult patients with advanced non-small cell lung cancer (NSCLC) harboring a BRAFV600E mutation.
  • The approval is based on the Phase II PHAROS trial, which demonstrated a 75% objective response rate in treatment-naive patients and 46% in previously treated patients.
  • Updated results from the PHAROS trial showed that 64% of treatment-naive patients maintained a response for at least 12 months, with a median duration of response of 40 months.
  • The combination offers a new targeted therapy option for NSCLC patients with BRAFV600E mutations, addressing a significant unmet need in this population.

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

NCT03915951Active, Not RecruitingPhase 2
Pfizer
Posted 6/4/2019

Zealand Pharma's Dapiglutide Shows Promising Weight Loss in Phase 1b Trial

  • Zealand Pharma's dapiglutide demonstrated up to 8.3% placebo-adjusted mean weight loss after 13 weekly doses in a Phase 1b trial.
  • The trial assessed dapiglutide at doses up to 13 mg, showing it was safe and well-tolerated, with gastrointestinal adverse events consistent with incretin-based therapies.
  • A Phase 2b trial in overweight and obese individuals is planned for the first half of 2025, following further evaluation of higher doses up to 26 mg in an ongoing trial.
  • Dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist, is being developed for weight management and potential benefits in obesity-related comorbidities.

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

NCT04612517CompletedEarly Phase 1
Zealand Pharma
Posted 10/26/2020

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

NCT06000891TerminatedPhase 1
Zealand Pharma
Posted 9/15/2023

Metabolic Profiling at Birth Shows Promise in Identifying Infants at Risk of SIDS

  • A recent case-control study links abnormal newborn metabolic profiles with an increased risk of Sudden Infant Death Syndrome (SIDS).
  • Elevated levels of free carnitine and C-14OH show a positive correlation with SIDS risk, while increased C-3, C-5DC, and C-12:1 levels are linked to lower risk.
  • A predictive model incorporating metabolic markers and other factors demonstrates good accuracy in identifying infants at higher SIDS risk.
  • The findings suggest that expanded newborn metabolic screening could enable targeted interventions and further research into SIDS mechanisms.

Emerging Therapies Nemolizumab and Lebrikizumab Poised to Reshape Atopic Dermatitis Market

  • Galderma's nemolizumab and Eli Lilly's lebrikizumab are anticipated to significantly alter dermatologist perceptions and treatment strategies for atopic dermatitis.
  • Adbry has shown substantial growth and now rivals Rinvoq, which has seen its usage stabilize since 2022, indicating a shift in treatment preferences.
  • Dermatologists estimate that advanced systemic treatments are now used in two-fifths of adult atopic dermatitis patients, reflecting a growing demand for effective therapies.
  • Nemolizumab's mechanism of action targeting IL-31 is increasingly favored over IL-13, potentially driving its adoption, especially for patients with severe itch.

Trending News

1

Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance One-Time Gene Editing Treatments for Cardiovascular Disease

4 days ago
2

Eli Lilly Acquires Gene-Editing Biotech Verve Therapeutics for $1.3 Billion to Expand Cholesterol Treatment Pipeline

5 days ago
3

AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint

5 days ago
4

FDA Approves CSL's ANDEMBRY for Hereditary Angioedema Prevention with Novel Factor XIIa Targeting

5 days ago
5

FDA Approves Tafasitamab Triple Combination for Relapsed/Refractory Follicular Lymphoma

3 days ago
6

Samsung Biologics Expands Into Preclinical Research with Launch of Samsung Organoids Drug Screening Platform

6 days ago
7

AbbVie's Atogepant Demonstrates Superior Tolerability and Efficacy Over Topiramate in Phase 3 Migraine Prevention Trial

3 days ago
8

D&D Pharmatech's DD01 Shows Rapid Liver Fat Reduction in MASH Phase 2 Trial, Matching Competitor Results in Quarter of the Time

5 days ago
9

Draig Therapeutics Emerges from Stealth with $140M to Advance Novel Neuropsychiatric Therapies

3 days ago
10

NHS App to Feature Clinical Trial Matching System as UK Targets 150-Day Setup Times

6 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy